Metabolomics Analysis of the Osteogenic Differentiation of Umbilical Cord Blood Mesenchymal Stem Cells Reveals Differential Sensitivity to Osteogenic Agents

Michail E. Klontzas,^{1,*} Spyros I. Vernardis,^{1,*} Manolis Heliotis,² Eleftherios Tsiridis,^{3,4} and Athanasios Mantalaris¹

Mesenchymal stem cells (MSCs) of fetal origin, such as umbilical cord blood MSCs (UCB MSCs), have emerged as a promising cell source for musculoskeletal tissue regeneration because of their higher proliferation potential, lack of donor site morbidity, and their off-the-shelf potential. MSCs differentiated toward the osteogenic lineage exhibit a specific metabolic phenotype characterized by reliance to oxidative phosphorylation for energy production and reduced glycolytic rates. Currently, limited information exists on the metabolic transitions at different stages of the osteogenic process after osteoinduction with different agents. Herein, the osteoinduction efficiency of BMP-2 and dexamethasone on UCB MSCs was assessed using gas chromatography–mass spectrometry (GC-MS) metabolomics analysis, revealing metabolic discrepancies at 7, 14, and 21 days of induction. Whereas both agents when administered individually were able to induce collagen I, osteocalcin, and osteonectin expression, BMP-2 was less effective than dexamethasone in promoting alkaline phosphatase expression. The metabolomics analysis revealed that each agent induced distinct metabolic alterations, including changes in amino acid pools, glutaminolysis, one-carbon metabolism, glycolysis, and tricarboxylic acid cycle. Importantly, we showed that in vitro-differentiated UCB MSCs acquire a metabolic physiology similar to primary osteoblasts when induced with dexamethasone but not with BMP-2, highlighting the fact that metabolomics analysis is sensitive enough to reveal potential differences in the osteogenic efficiency and can be used as a quality control assay for evaluating the osteogenic process.

Keywords: mesenchymal stem cells, cord blood, metabolomics, metabolism, osteogenesis, osteoblasts

Introduction

MESENCHYMAL STEM CELLS (MSCs) are multipotent cells that are widely used in musculoskeletal tissue regeneration, which currently accounts for the largest share of the global tissue engineering market [1,2]. MSCs isolated from various sources have been investigated for their osteogenic potential. MSCs derived from fetal tissues, such as umbilical cord matrix, amniotic fluid, and umbilical cord blood (UCB) have emerged as an attractive alternative to adult MSCs, because of their higher proliferation potential, lack of donor site morbidity, and the possibility of their off-the-shelf use for the production of personalized autologous bone grafts [3,4].

Metabolism represents the cellular function used by cells to react first to environmental stimuli and to manifest changes to the cellular physiology. During proliferation, bone marrow MSCs exhibit a glycolytic phenotype with increased reactive oxygen species (ROS) production [5] while at the same time retaining oxidative phosphorylation (OXPHOS) for partial energy production [6]. However, when differentiated to osteoblasts in vitro, their energy production is based on OXPHOS associated with increased biogenesis of mitochondria and a reduction of ROS production [5,7].

Metabolomics affords global analysis of the cellular metabolic state and has already been proven useful as a sensitive tool for cell culture monitoring [8]; it can be applied to study

¹Biological Systems Engineering Laboratory, Department of Chemical Engineering and Chemical Technology, Imperial College London, London, United Kingdom.

²Department of Oral and Maxillofacial Surgery, London North West Healthcare NHS Trust, Northwick Park Hospital, London, United Kingdom.

³Academic Orthopaedic Unit, Aristotle University Medical School, Thessaloniki, Greece.

⁴Department of Surgery and Cancer, Division of Surgery, Imperial College London, London, United Kingdom.

*These authors contributed equally to this work.

© Michail E. Klontzas et al. 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mary Ann Liebert, Inc. offers reprint services for those who want to order professionally produced copies of articles published under the Creative Commons Attribution (CC BY) license. To obtain a price quote, email Reprints@liebertpub.com. Please include the article's title or DOI, quantity, and delivery destination in your email.

stem cell metabolic physiology [9], enabling elucidation of the metabolic network state. It enables multivariate analysis that accounts for correlations between metabolic pathways that are neglected by traditional enzyme activity tests for a limited number of enzymes and analyses involving only specific metabolites. This is important as minuscule changes in metabolite concentrations can prove significant when multiple metabolites are simultaneously analyzed, whereas the same would not be possible when using one-at-a-time analyses. Specifically, stem cell metabolomics research has revealed that the metabolome is not only affected by cellular processes, such as proliferation and differentiation, but can also regulate the epigenetic state of embryonic stem cells (ESCs) [10] and control the balance between proliferation and differentiation of naive and primed human pluripotent stem cells [11]. In addition, it has been used in the identification of small molecules secreted by ESCs when exposed to valproate [12] and steroid hormones [13] and for the monitoring of chondrogenesis of MSCs [14]. Metabolome differences in lipid and primary metabolism between induced pluripotent stem cells and ESCs [15] and between MSCs cultured on titanium nanopillars compared with those cultured on plastic [9] have indicated that environmental or genetic perturbations and biomaterial surface have important consequences on the metabolic physiology of stem cells. Finally, Muñoz et al. reported differences on glutaminolysis, tricarboxylic acid (TCA) cycle, and malate–aspartate shuttle when osteogenically induced MSCs were exposed to normoxia and hypoxia [16].

Current knowledge of the metabolism of MSCs, mainly based on enzyme activity and extracellular metabolite studies, has showed that in vitro-differentiated MSCs exhibit a specific metabolic phenotype [5–7,17]. However, the accepted universal feature of osteogenesis involving the metabolic shift to OXPHOS and associated reduced glycolytic rates neglects the fact that various osteoinductive agents have differential efficiencies. In addition, no direct comparison has been performed on the metabolome of primary osteoblasts and in vitro-differentiated MSCs. Even though MSCs can (inefficiently) differentiate in the absence of osteoinductive signals, efficient differentiation strategies require osteoinductive agents, such as dexamethasone and BMP-2 [18,19].

Herein, we demonstrate that differences exist in the ability of dexamethasone and BMP-2 to induce osteogenesis of UCB MSCs. We show by performing time-course metabolomics analysis of the osteogenic differentiation process over 21 days that UCB MSCs go through various metabolic states before acquiring their final metabolic phenotype, which is treatment dependent. This work highlights the fact that metabolic physiology reflects the degree of MSC osteogenic differentiation and signifies the use of metabolomics as a sensitive and robust tool for bioprocess monitoring and optimization.

Materials and Methods

UCB MSC isolation and maintenance

UCB MSCs were isolated from full-term UCB units (NHS Blood & Transplant, Colindale Blood Bank) after obtaining maternal consent according to the relevant ethical approval (05/Q0405/20; NRES Committee, London, Harrow). Blood was processed within 24 hours from bleeding and the mononuclear fragment was isolated by Ficoll density gradient centrifugation. In brief, blood was diluted 1:4 with phosphate-

buffered saline (PBS) (Life Technologies, United Kingdom), layered on Ficoll (Ficoll-paque; GE Healthcare, United Kingdom), and centrifuged. The mononuclear layer was subsequently aspirated, washed with PBS, resuspended in α MEM GlutaMax-I (Gibco; Life Technologies, United Kingdom) with 10% fetal bovine serum (FBS) (Gibco; Life Technologies, United Kingdom) and 1% penicillin/streptomycin (Sigma-Aldrich, United Kingdom), and seeded in 75 cm² plastic culture flasks. After 48 h, the supernatant was removed and the adherent cells were further cultured with the same culture medium under 37°C, 21% O₂, and 5% CO₂. Culture medium was changed twice a week and cells were passaged before reaching 80% confluence. Cells between passages 4 and 6 were used for subsequent experiments.

Osteogenic induction and culture of primary osteoblasts

For osteogenic differentiation, the culture medium was supplemented with 10 mM β -glycerophosphate (Sigma-Aldrich, United Kingdom), 50 μ g/mL ascorbic acid 2-phosphate (Sigma-Aldrich, United Kingdom), and 10^{−7} M dexamethasone (Sigma-Aldrich, United Kingdom) or human recombinant BMP-2 (PeproTech, United Kingdom) at 100 ng/mL. Primary human osteoblasts isolated from humeral head cancellous bone (PromoCell GmbH, Germany) were used as a positive control group for metabolomics experiments. Cells were cultured with α MEM GlutaMAX, 10% FBS, 1% penicillin/streptomycin under 21% O₂, 5% CO₂, and 37°C, and metabolomic fingerprints were obtained at passage 4.

Alizarin red S staining and quantification

The effect of dexamethasone and BMP-2 on UCB MSC culture mineralization was evaluated by means of Alizarin red S staining (ARS) at pH 4.1 (Sigma-Aldrich, United Kingdom) and results were quantified according to Gregory et al. [20] by the addition of 10% acetic acid (Sigma-Aldrich, United Kingdom) to the stained culture flask, vortexing the resulting cell stain suspension, and heating to 85°C for 10 min. Subsequently, pH was fixed between 4.1 and 4.5 with 10% ammonium hydroxide (Sigma-Aldrich, United Kingdom) and absorbance values were read at 405 nm with an ELISA reader (ELx808; BioTek, United Kingdom).

DNA quantification

DNA quantification for data normalization purposes was performed as previously published [21] with the use of PicoGreen assay (ThermoFisher Scientific, United Kingdom). In brief, cells were washed with PBS and incubated for 6 h with 1 mL digestion buffer with 0.1% Triton X-100, 10 mM Tris, 1 mM EDTA (Sigma-Aldrich, United Kingdom), and 0.1 mg/mL proteinase K (ThermoFisher Scientific, United Kingdom) at 50°C with intermediate agitation. The resulting solution was diluted 10-fold in PBS and 100 μ L of each sample was incubated with 100 μ L of PicoGreen dye for 5 min at room temperature. Fluorescence was measured with a Promega GloMax multidetection system (Promega, United Kingdom) with excitation and emission wavelengths of 485 and 530 nm, respectively. Background fluorescence was then subtracted and number of cells were calculated based on a custom standard curve created with UCB MSCs.

Alkaline phosphatase activity

Activity of alkaline phosphatase (ALP) was evaluated by measuring its ability to hydrolyze *p*-nitrophenyl phosphate (pNPP) producing yellow *p*-nitrophenol. After washing cells with PBS, 200 μ L ALPase buffer (Sigma-Aldrich, United Kingdom) and 200 μ L pNPP solution were added to the culture and incubated for 30 min at 37°C in the dark. Sodium hydroxide 0.5 M (Sigma-Aldrich, United Kingdom) was used to terminate the reaction and absorbance at 405 nm was measured with an ELISA reader (ELx808; BioTek, United Kingdom). ALP activity was then expressed as μ M of *p*-nitrophenol/ 10^6 cells/min.

RNA extraction and real-time quantitative PCR

Total RNA was extracted with the use of RNeasy mini kit (Qiagen, United Kingdom) according to the manufacturer's instructions followed by real-time quantitative PCR (RT-qPCR) with the use of KAPA SYBR FAST 1-step qRT-PCR kit (Kapa Biosystems Ltd., United Kingdom) based on the manufacturer's instructions (5 min reverse transcription at 42°C, 3 min enzyme inactivation at 95°C, and 40 cycles of 3 s denaturation at 95°C and 30 s of annealing/extension at 62°C) in a StepOne Plus qRT-PCR instrument (Applied Biosystems, CA).

Expression of osteonectin, osteocalcin (OCN), ALP, and runt-related transcription factor 2 (Runx2) mRNA was quantified with the use of the following primers: ALP [22] (forward) 5'-GGACCATTCCCACGTCTTCAC-3', (reverse) 5'-CCTTGTAGCCAGGCCCATTC-3'; osteonectin [23] (forward) 5'-TCCACAGTACCGGATTCTCTCT-3', (reverse) 5'-TCTATGTTAGCACCTTGTCTCCAG-3'; OCN [24] (forward) 5'-CCCAGGCGCTACCTGTATCAA-3', (reverse) 5'-GGTCAGCCAACCTCGTCACAGTC-3'; Runx2 [25] (forward) 5'-GAGGTACCAGATGGGACTGTG-3', (reverse) 5'-TCGTTGAACCTTGCTACTTGG-3'; and RPL13a [23,26] (forward) 5'-CTATGACCAATAGGAAGAGCAA-3', (reverse) 5'-GCAGAGTATATGACCAGGTGGAA-3'. Results were normalized with the use of RPL13a as the housekeeping gene and expressed as fold change relative to day 0 based on the $2^{-\Delta\Delta C_t}$ method [27].

Immunofluorescence

Cumulative secretion of OCN and collagen type I A1 over the whole differentiation period in the extracellular matrix was assessed by means of immunofluorescence. Cells were washed with PBS and fixed with 4% paraformaldehyde solution (Sigma-Aldrich, United Kingdom) and subsequently blocked with a solution of 3% donkey or goat serum (Sigma-Aldrich, United Kingdom) for 1 h at room temperature to avoid nonspecific antibody binding. After overnight treatment with primary antibodies at 4°C, they were incubated with FITC- or PE-conjugated antibodies (Santa-Cruz Biotech), counterstained with 4,6-diamidino-2-phenylindole (DAPI) and images were taken with a BX-51 Olympus microscope (Olympus, United Kingdom). Details regarding antibodies and dilutions can be found in Table 1.

Metabolomics analysis

Sampling was performed before the beginning of differentiation and every 7 days until day 21. Metabolite extraction was carried out as previously described [8]. Ribitol (1 mg/ 10^6

TABLE 1. ANTIBODIES USED FOR IMMUNOFLUORESCENCE

Antigen	Blocking serum	Primary antibody	Secondary antibody
Collagen type I A1	Mouse serum	Rabbit polyclonal (1:80 dilution)	Mouse antirabbit IgG-FITC (1:100 dilution)
Osteocalcin	Donkey serum	Goat polyclonal (1:50 dilution)	Donkey anti-goat IgG-PE (1:100 dilution)

cells) and [UC-13]-glucose (2 mg/ 10^6 cells) were used as internal standards, and dried polar metabolite extracts were derived. Number of cells estimation for the purposes of data normalization was performed with the use of DNA quantification [28]. A precise number of cells extrapolation method is essential analysis of differentiated cultures, in which cells are enclosed in dense, mineralized extracellular matrix and single cell counting is not possible. Methoxyamine hydrochloride (Sigma-Aldrich, United Kingdom) and *N*-methyltrimethylsilyl-trifluoroacetamide (Alfa Aesar, United Kingdom) were used for the derivatization steps [29,30].

Metabolic profiles were obtained with the use of a Shimadzu QP2010 Ultra GC-MS (Shimadzu Corp., Milton Keynes, United Kingdom). Data validation, normalization, and filtering were accomplished according to Kanani and Klapa [29] and the peak area of the marker ion 103 of ribitol was used for the calculation of the relative peak areas (RPAs) of all detected peaks. The resulting normalized and filtered RPAs, according to the Kanani and Klapa method [30], consisted of 50 metabolites that were used for further data analysis. Analysis was performed on data from three biological replicates for each group at each time point.

Metabolomic multivariate data analysis was carried out with TM4 MeV (v. 4.9.0) [31] on the standardized RPAs of metabolites. Hierarchical clustering (HCL) with Manhattan distance metric and principal component analysis (PCA) were used as unsupervised multivariate algorithms to observe patterns in our data and explore sample differences based on their metabolic profiles. Significantly increased or decreased metabolites between our groups were identified with the use of significance analysis of microarrays (SAM), with delta scores yielding a false discovery rate of 0%. All significant metabolite changes were depicted on a reconstruction of the basic metabolic network of UCB MSCs.

Statistical analysis

Statistical analysis of ARS quantification, ALP activity, RT-qPCR as well as proliferation data was performed with OriginPro 2016 (b9.3.2.303; OriginLab Corporation, Northampton, MA) with the use of ANOVA and Tukey's posthoc test ($n=3$ independent biological replicates). All values are expressed as mean $\pm$ standard deviation and statistical significance was set at a *P* value less than 0.05.

Results

BMP-2 is less efficient than dexamethasone in inducing osteogenesis of UCB MSCs

The ability of BMP-2 and dexamethasone to induce osteogenic differentiation and bone extracellular matrix

FIG. 1. Alizarin red S staining (A) and alkaline phosphatase (ALP) activity (B) analyses over 21 days of differentiation. Bars represent mean $\pm$ standard deviation ($n = 3$); * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; BMP2, BMP-2 group; Con, control group; Dex, dexamethasone group.

production was evaluated over 21 days. To clearly assess their osteoinductive effects, each osteoinductive agent was applied individually. Direct comparison of the two groups showed that at day 7, mineralization in the BMP-2 group was not significantly higher than in the control group ($P = 0.259$) in contrast to dexamethasone-treated cells that exhibited significant mineralization ($P < 0.05$). At day 14, there was no significant difference between the mineralization of the two groups, which was higher than that of the control ($P < 0.05$), whereas at day 21, mineralization of the dexamethasone group was higher than that of the BMP-2 group ($P < 0.001$), as shown in Fig. 1A. ALP activity analysis further highlighted the differences between BMP-2 and dexamethasone. Specifically, BMP-2 failed to increase ALP activity compared with the control group; in contrast, dexamethasone significantly increased ALP activity throughout osteogenic differentiation ($P < 0.001$ at days 7 and 14, $P < 0.01$ at day 21), as shown in Fig. 1B. These results were corroborated by ALP gene expression in which dexamethasone significantly upregulated ALP gene expression ($P < 0.001$) at day 21, whereas BMP-2 had no influence, remaining at the same level as the control ($P = 0.48$, as shown in Fig. 2A).

Expression of the rest of the osteogenic genes revealed that both dexamethasone and BMP-2 resulted in four times higher osteonectin mRNA levels than the control group ($P < 0.01$) and that Runx2 expression had no significant difference between the two groups. At day 21, no significant changes were noticed between the OCN mRNA levels of the control and the BMP-2 groups, whereas OCN gene expression was significantly downregulated by dexamethasone at this time point (Fig. 2A) ($P < 0.05$). However, immunofluorescence analysis showed that dexamethasone resulted in overall higher cumulative extracellular secretion of OCN and collagen type I over the whole differentiation period than BMP-2 (Fig. 2B). No difference in the proliferation rates was found between the two groups at days 7 and 14 of

differentiation, although at the end of the differentiation period at day 21, the BMP-2 group had fewer cells (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/scd).

Differences in the osteogenic efficacy of dexamethasone and BMP-2 are associated with distinct metabolic transitions

Metabolomics analysis was performed to evaluate the effects of dexamethasone and BMP-2 on the metabolism of UCB MSCs during osteogenesis and to compare with undifferentiated MSCs and primary osteoblasts. Analysis of metabolic profiles of cells stimulated with dexamethasone revealed a distinct pattern of metabolic transitions from undifferentiated to terminally differentiated cells. Specifically, PCA showed that exposure to either dexamethasone (Fig. 3A) or BMP-2 (Fig. 3B) resulted in cells transitioning to a metabolic state different from that of untreated cells. The day 7 metabolomics profile of dexamethasone-treated cells was different from that of days 14 or 21; interestingly, the metabolomics profile of day 21 dexamethasone-treated cells was similar to that of primary osteoblasts (Fig. 3A). In contrast, the metabolomics profiles of BMP-2-treated cells were relatively similar to each other; more importantly, the terminally differentiated day 21 BMP-2-treated cells displayed a metabolomics profile that was significantly different compared with that of human primary osteoblasts.

Unsupervised HCL identified distinct clusters in both the BMP-2 and dexamethasone groups. In the dexamethasone group (Fig. 4A), undifferentiated cells and day 7 cells formed two distinct clusters, whereas days 14 and 21 cells clustered together with osteoblasts. In addition, day 7 dexamethasone-treated cells were characterized by global metabolic hyperactivity. Unsupervised HCL of BMP-2-treated cells (Fig. 4B) was vastly different, as undifferentiated cells and osteoblasts

FIG. 2. Expression of osteogenic markers. (A) Real-time quantitative PCR analysis of ALP, osteonectin, osteocalcin (OCN), and Runx2 at day 21 of osteogenic induction. Results are normalized with RPL13a as the reference gene and expressed as fold change relative to day 0. Bars represent mean $\pm$ standard deviation ($n = 3$); Con: control group; Dex: dexamethasone group; BMP2: BMP-2 group. (B) Cumulative secretion of extracellular matrix proteins (collagen type I and OCN) over 21 days of osteogenic stimulation, as shown by immunofluorescence at day 21. Fluorescein isothiocyanate (green) denotes collagen expression, whereas phycoerythrin (red) denotes OCN expression. Cells were counterstained with DAPI (blue). Insets represent negative controls for nonspecific staining of the secondary antibody; Scale bar = 200 μ m; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

FIG. 3. Principal component analysis of dexamethasone (A) and BMP-2 (B) stimulated cells. Green, magenta, yellow, blue, and white represent undifferentiated, days 7, 14, 21, and human primary osteoblast cells, respectively; PC1, data variation described by principal component 1; PC2, data variation described by principal component 2; PC3, data variation described by principal component 3.

formed separate clusters and the profiles of BMP-2-treated cells matched with each other in a mixed clustering pattern. Importantly, none of the BMP-2-stimulated cells clustered together with osteoblasts.

SAM was utilized to reveal significant changes in individual metabolite concentrations over the differentiation time course, resulting in the reconstruction of the metabolic network, as shown in Fig. 5. As cells transitioned from the undifferentiated state to early stage of osteogenic induction (day 7), significant increases in concentration were observed in the amino acid pools in both groups. In addition, the concentration of glutamine, cholesterol, one-carbon metabolism intermediates (eg, serine, threonine, and methionine), phospholipid, and glycerolipid precursors (eg, glycerol and myoinositol) was significantly increased only in the dexamethasone group (Supplementary Table S1). The same changes in the BMP-2 group were observed, alas with a 7-day delay (day 14), whereby glucose, TCA cycle intermediates (eg, fumarate and citrate), and glutamate were significantly increased. In the dexamethasone-treated group, cells started to reduce the concentration of amino acids, lactate, lipid precursors as well as urea cycle (ornithine) and one-carbon metabolism intermediates at day 14 (Supplementary Table S2).

At the final day of osteoinduction (day 21), the concentrations of TCA cycle, glycolysis, and glutaminolysis intermediates kept decreasing in both groups compared with the previous time point (day 14). In addition, unique changes in the day-21 dexamethasone-treated group included a further decrease in amino acid pools as well as increased concentrations of lipid-related molecules (eg, cholesterol and glycerol) and ornithine. Interestingly, the BMP-2-treated group at day 21 qualitatively displayed similar changes as those observed in day-14 cells stimulated with dexamethasone (Supplementary Table S3). A comparison of the metabolite concentrations of

the terminally differentiated cells with those of primary osteoblasts revealed that osteoblasts had significantly higher glycerolipid and lower phospholipid precursors as well as lower lactate and glutamine levels than the day-21 BMP-2 treated cells (Fig. 5). In contrast, osteoblasts had lower glucose, lactate, glutamine, lipid precursors, and TCA cycle (citrate, isocitrate, and fumarate) levels than day-21 dexamethasone-treated cells (Fig. 5 and Supplementary Table S4).

Discussion

A comprehensive analysis of UCB MSC metabolism during osteogenesis employing two of the most commonly used osteoinductive agents, dexamethasone and BMP-2, was performed. BMP-2 was shown to be less effective than dexamethasone in inducing UCB MSC osteogenesis. Importantly, metabolic profiling revealed differences in the osteogenic capacity of both agents and proved that cells undergo specific metabolic alterations before reaching a terminal metabolic state that reflected their degree of differentiation.

Metabolomics comparison of in vitro-differentiated cells and primary human osteoblasts demonstrated that metabolomics has the potential to accurately capture the extent of osteogenic differentiation. Despite the variability in osteogenic marker expression, metabolomics described the overall differentiation process and revealed the differentiation stage of the cells, suggesting using metabolic profiling as a tool of monitoring stem cell bioprocesses, such as maintenance and differentiation, and establishing quality control criteria for both the bioprocess and the product. Similar analyses have been employed to investigate the effects of different culture conditions on MSC metabolism during differentiation. Specifically, Muñoz et al. showed that MSCs rely on high oxygen concentration for their successful osteogenic differentiation when stimulated with

FIG. 4. Hierarchical clustering of dexamethasone (A) and BMP-2 (B) stimulated cells. Red and green heat-map colors represent increased or decreased normalized relative peak areas of each respective metabolite. Semitransparent coloring of the dendrogram (faded green/red) indicates clusters formed with the dendrogram cut at distance 43.

FIG. 5. On-network time-course analysis of significant metabolite changes during osteogenic differentiation. *Red* and *green* represent a significantly increased or decreased metabolite with regard to the previous time point/condition, respectively. *White* indicates no significant change in the metabolite level compared with the previous time point/condition; 7, 14, 21, and O represent days 7, 14, 21, and osteoblasts, respectively.

dexamethasone for 21 days and subsequently cultured for 3 days under either hypoxic or normoxic conditions [16]. Alas, in their study, metabolomics analysis was performed after completing the osteogenic differentiation process for 21 days in normoxia and consequently overlooking the potential role of hypoxia during the osteogenic differentiation of MSCs as well as not correlating the metabolomics results to gene expression [32–34]. Utilization of metabolomic profiles as biomarkers of MSC differentiation was also suggested by Jang et al., who used nuclear magnetic resonance spectroscopy to monitor chondrogenesis [14]. Surrati et al. [35] monitored osteogenesis of mouse MSCs with the use of dexamethasone by performing metabolomics of the culture medium, finding increased TCA cycle and glycerol derivatives in the medium. Nevertheless, their approach is limited

by the fact that extracellular metabolites provide only a rough approximation of intracellular metabolism [36].

UCB MSC differentiation employing dexamethasone was characterized by fluctuations in cellular metabolic activity. The activation of pathways related to lipid and protein biosynthesis as well as energy production during the onset of osteogenic differentiation (day 7) could be attributed to a metabolic shift toward gluconeogenesis as observed in cancer cells stimulated by glucocorticoids such as dexamethasone [37]. However, the fact that glucose was provided in excess in the culture medium did not facilitate the detection of intracellular glucose production because of gluconeogenesis. Cells could have also increased their metabolic activity as a result of increased proliferation [38,39], a possibility that is not supported as proliferation

was found similar between the dexamethasone- and BMP-2-treated groups. Therefore, the most plausible explanation for this phenomenon is that in response to dexamethasone, cells increase their metabolic rates to support the induction of the differentiation processes that require building blocks (eg, amino acids and lipids). Nonetheless, further research is needed to elucidate the exact mechanism(s) responsible for this phenomenon. Metabolic fluctuations of smaller magnitude noticed in BMP-2-stimulated cells were proven less significant than those in the dexamethasone group. These observations highlight the fact that metabolism changes significantly during (osteogenic) differentiation and is agent-specific, necessitating the development of “dynamic application- and agent-specific” bioprocesses (including culture media), because current protocols use the same culture medium and provide the same nutrients throughout the culture process irrespective of maintenance or differentiation protocols [40].

In terms of energy production, UCB MSCs displayed a less proliferative metabolic phenotype toward the end of differentiation (day 21) using dexamethasone, reflected by reduced glycolytic rates, TCA cycle, and glutaminolysis activities. These findings are in agreement with Chen et al. who showed increased mitochondrial activity and decreased intracellular ROS during dexamethasone-induced osteogenic differentiation of bone marrow MSCs, suggesting a transition from glycolysis to OXPHOS during osteogenesis [5]. Similarly, Pattappa et al. showed that, in contrast to MSCs differentiated toward the chondrogenic lineage, those differentiated toward the osteogenic lineage with the use of dexamethasone retained high oxygen consumption and, therefore, an oxidative phenotype throughout the process [6]. However, our findings differ from the results of Shum et al. [7], who showed that glycolytic rates remained the same in undifferentiated cells despite the increase in OXPHOS. This discrepancy is explained by the fact that Shum et al. investigated bone marrow MSCs that were not stimulated with dexamethasone and confined their study at the transcriptome rather than the metabolome.

Threonine and one-carbon cycle metabolism were correlated with the degree of differentiation earlier in the dexamethasone group (day 7) and delayed in the BMP-2 group (day 14). The activity of these pathways was reduced by both agents at the end of the differentiation process (day 21). These findings correlate with the loss of stemness associated with differentiation as suggested by results demonstrating that mouse pluripotent stem cells rely on threonine catabolism, one-carbon metabolism, and folate pools for maintaining pluripotency, which is lost when deprived of threonine [41].

Human UCB MSCs were less responsive to BMP-2 than to dexamethasone. BMP-2 is an osteoinductive growth factor that has received FDA approval for use in patients [42]. Although it is considered a potent stimulator of the osteogenic process, it is well established that responsiveness of MSCs to BMP-2 varies according to factors such as the MSC source and the age of the donor [43,44]. Responsiveness to BMP-2 also varies between species as rat bone marrow MSCs consistently increase their ALP activity when exposed to BMP-2, whereas human MSCs require the presence of dexamethasone along with BMP-2 to achieve the same ALP enzyme activity and mRNA levels [45–47]. Osteoblastic gene transcription and bone extracellular matrix synthesis further confirmed that BMP-2 cells achieved

an extent of osteogenic differentiation, which was inferior to that observed in the dexamethasone group. The inability of BMP-2 to activate Runx2, shown by Osyczka et al. [48], or the low expression of BMP-2 receptors, which is significantly increased when dexamethasone is coadministered with BMP-2 [45], provides plausible explanations of our results.

Downregulation of OCN under the effect of dexamethasone at day 21 was in agreement with the results of Wang et al., who showed that OCN in UCB MSCs increases during the second week of differentiation followed by a dramatic decrease at the end of differentiation, reaching levels lower than the control group [49]. Such an early increase in OCN followed by a late decrease in its expression levels could also be indicated by the fact that the secretion of OCN in the extracellular matrix was higher in our dexamethasone group. The more efficient cumulative secretion of OCN in dexamethasone-treated cells over 21 days could also be attributed to differences in protein translation or post-translational modifications at some point during the 3-week process. The increasing clinical importance of both UCB MSCs and BMP-2 highlights the importance of our observations. Nevertheless, it is critical to stress that in vitro results differ from in vivo data, in which circulating endogenous glucocorticoids may potentiate the action of exogenously administered BMP-2.

In conclusion, differences in the osteogenic efficiency of dexamethasone and BMP-2-treated UCB MSCs were observed through the use of metabolomics with BMP-2 being less effective. Comprehensive metabolic analysis represents a sensitive and efficient monitoring tool in elucidating key pathways activated during various stages of a stem cell bioprocess, such as differentiation, and can be utilized for the optimization of culture conditions and the development of optimal and robust bioprocesses as well for quality control of the bioprocess and the cell product, as stem cell-based cellular therapies achieve increasing clinical significance.

Acknowledgment

This project has received funding from the European Union's Horizon 2020 research and innovation program, under the Marie Skłodowska-Curie grant agreement no. 675585.

Author Disclosure Statement

No competing financial interests exist.

References

1. Schachter B. (2014). Therapies of the state. *Nat Biotech* 32:736–741.
2. Barry FP and JM Murphy. (2004). Mesenchymal stem cells: clinical applications and biological characterization. *Int J Biochem Cell B* 36:568–584.
3. Klontzas ME, EI Kenanidis, M Heliotis, E Tsiroidis and A Mantalaris. (2015). Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells. *Expert Opin Biol Ther* 15:1541–1552.
4. Flynn A, F Barry and T O'Brien. (2007). UC blood-derived mesenchymal stromal cells: an overview. *Cytotherapy* 9:717–726.

5. Chen C-T, Y-R Shih, TK Kuo, OK Lee and Y-H Wei. (2008). Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. *Stem Cells* 26:960–968.
6. Pattappa G, HK Heywood, JD de Bruijn and DA Lee. (2011). The metabolism of human mesenchymal stem cells during proliferation and differentiation. *J Cell Physiol* 226:2562–2570.
7. Shum LC, NS White, BN Mills, KL de Mesy Bentley and RA. Eliseev. (2016). Energy metabolism in mesenchymal stem cells during osteogenic differentiation. *Stem Cells Dev* 25:114–122.
8. Vernardis SI, CT Goudar and MI Klapa. (2013). Metabolic profiling reveals that time related physiological changes in mammalian cell perfusion cultures are bioreactor scale independent. *Metab Eng* 19:1–9.
9. McNamara LE, T Sjöström, RMD Meek, ROC Oreffo, B Su, MJ Dalby and KE Burgess. (2012). Metabolomics: a valuable tool for stem cell monitoring in regenerative medicine. *J R Soc Interface* 9:1713–1724.
10. Sperber H, J Mathieu, Y Wang, A Ferreccio, J Hesson, Z Xu, KA Fisher, A Devi, D Detraux, et al. (2015). The metabolome regulates the epigenetic landscape during naive to primed human embryonic stem cell transition. *Nat Cell Biol* 17:1523–1535.
11. TeSlaa T, AC Chaikovsky, I Lipchina, SL Escobar, K Hochedlinger, J Huang, TG Graeber, D Braas, MA Teitell. (2016). α -ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. *Cell Metab* 24:485–493.
12. Cezar GG, JA Quam, AM Smith, GJM Rosa, MS Piekarczyk, JF Brown, FH Gage and AR Muotri. (2007). Identification of small molecules from human embryonic stem cells using metabolomics. *Stem Cells Dev* 16:869–882.
13. West FD, WM Henderson, P Yu, JY Yang, SL Stice and MA Smith. (2012). Metabolomic response of human embryonic stem cell-derived germ-like cells after exposure to steroid hormones. *Toxicol Sci* 129:9–20.
14. Jang M-Y, S-I Chun, C-W Mun, KS Hong and J-W Shin. (2013). Evaluation of metabolomic changes as a biomarker of chondrogenic differentiation in 3D-cultured human mesenchymal stem cells using proton (1H) nuclear magnetic resonance spectroscopy. *PLoS One* 8:e78325.
15. Meissen JK, BTK Yuen, T Kind, JW Riggs, DK Barupal, PS Knoepfler and O Fiehn. (2012). Induced pluripotent stem cells show metabolomic differences to embryonic stem cells in polyunsaturated phosphatidylcholines and primary metabolism. *PLoS One* 7:e46770.
16. Muñoz N, J Kim, Y Liu, TM Logan and T Ma. (2014). Gas chromatography-mass spectrometry analysis of human mesenchymal stem cell metabolism during proliferation and osteogenic differentiation under different oxygen tensions. *J Biotechnol* 169:95–102.
17. Forni FM, J Peloggia, K Trudeau, O Shiriha and AJ Kowaltowski. (2016). Murine mesenchymal stem cell commitment to differentiation is regulated by mitochondrial dynamics. *Stem Cells* 34:743–755.
18. Jaiswal N, SE Haynesworth, AI Caplan and SP Bruder. (1997). Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. *J Cell Biochem* 64:295–312.
19. Khosla S, JJ Westendorf and MJ Oursler. (2008). Building bone to reverse osteoporosis and repair fractures. *J Clin Invest* 118:421–428.
20. Gregory CA, W Grady Gunn, A Peister and DJ Prockop. (2004). An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. *Anal Biochem* 329:77–84.
21. Grayson WL, M Fröhlich, K Yeager, S Bhumiratana, ME Chan, C Cannizzaro, LQ Wan, XS Liu, XE Guo and G Vunjak-Novakovic. (2010). Engineering anatomically shaped human bone grafts. *Proc Natl Acad Sci* 107:3299–3304.
22. Terao Y, S Satomi-Kobayashi, K Hirata and Y Rikitake. (2015). Involvement of Rho-associated protein kinase (ROCK) and bone morphogenetic protein-binding endothelial cell precursor-derived regulator (BMPER) in high glucose-increased alkaline phosphatase expression and activity in human coronary artery smooth muscle c. *Cardiovasc Diabetol* 14:104.
23. Quiroz FG, OM Posada, D Gallego-Perez, N Higuera-Castro, C Sarassa, DJ Hansford, P Agudelo-Florez and LE López. (2010). Housekeeping gene stability influences the quantification of osteogenic markers during stem cell differentiation to the osteogenic lineage. *Cytotechnology* 62:109–120.
24. Bin MY, X Li, ZY Li, J Zhao, XB Yuan, Y Ren, ZD Cui, YD Liu and XJ Yang. (2015). MicroRNA-21 promotes osteogenic differentiation of mesenchymal stem cells by the PI3K/ β -catenin pathway. *J Orthop Res* 33:957–964.
25. Turksen K. (2013). *Stem Cell Nanotechnology: Methods and Protocols*. Humana Press, New York.
26. Studer D, S Lischer, W Jochum, M Ehrbar, M Zenobi-Wong and K Maniura-Weber. (2012). Ribosomal protein L13a as a reference gene for human bone marrow-derived mesenchymal stromal cells during expansion, adipogenic, chondro-, and osteogenesis. *Tissue Eng Part C* 18:761–771.
27. Livak KJ and TD Schmittgen. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* 25:402–408.
28. Silva LP, PL Lorenzi, P Purwaha, V Yong, DH Hawke and JN Weinstein. (2013). Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines. *Anal Chem* 85:9536–9542.
29. Kanani H, PK Chrysanthopoulos and MI Klapa. (2008). Standardizing GC-MS metabolomics. *J Chromatogr B* 871:191–201.
30. Kanani HH and MI Klapa. (2007). Data correction strategy for metabolomics analysis using gas chromatography-mass spectrometry. *Metab Eng* 9:39–51.
31. Saeed AI, V Sharov, J White, J Li, W Liang, N Bhagabati, J Braisted, M Klapa, T Currier, et al. (2003). TM4: a free, open-source system for microarray data management and analysis. *Biotechniques* 34:374–378.
32. Aubin JE. (2001). Regulation of osteoblast formation and function. *Rev Endocr Metab Disord* 2:81–94.
33. Beederman M, JD Lamplot, G Nan, J Wang, X Liu, L Yin, R Li, W Shui, H Zhang, et al. (2013). BMP signaling in mesenchymal stem cell differentiation and bone formation. *J Biomed Sci Eng* 6:32–52.
34. Granchi D, G Ochoa, E Leonardi, V Devescovi, SR Baglio, L Osaba, N Baldini and G Ciapetti. (2010). Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion. *Tissue Eng Part C* 16:511–524.
35. Surrati A, R Linforth, ID Fisk, V Sottile and D-H Kim. (2016). Non-destructive characterisation of mesenchymal stem cell differentiation using LC-MS-based metabolite fingerprinting. *Analyst* 141:3776–3787.

36. Villas-Bôas SG, JF Moxley, M Akesson, G Stephanopoulos and J Nielsen. (2005). High-throughput metabolic state analysis: the missing link in integrated functional genomics of yeasts. *Biochem J* 388:669–677.
37. Ma R, W Zhang, K Tang, H Zhang, Y Zhang, D Li, Y Li, P Xu, S Luo, et al. (2013). Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. *Nat Commun* 4:2508.
38. Heiden MG Vander, LC Cantley and CB Thompson. (2009). Understanding the Warburg effect: cell proliferation. *Science* 324:1029–1034.
39. Ito K and T Suda. (2014). Metabolic requirements for the maintenance of self-renewing stem cells. *Nat Rev Mol Cell Biol* 15:243–256.
40. Langenbach F and J Handschel. (2013). Effects of dexamethasone, ascorbic acid and β -glycerophosphate on the osteogenic differentiation of stem cells in vitro. *Stem Cell Res Ther* 4:117.
41. Wang J, P Alexander, L Wu, R Hammer, O Cleaver and SL McKnight. (2009). Dependence of mouse embryonic stem cells on threonine catabolism. *Science* 325:435–439.
42. Klontzas ME, EI Kenanidis, RJ MacFarlane, T Michail, ME Potoupnis, M Heliotis, A Mantalaris and E Tsiridis. (2016). Investigational drugs for fracture healing: preclinical & clinical data. *Expert Opin Investig Drugs* 25:585–596.
43. Osyczka AM, M Damek-Poprawa, A Wojtowicz and SO Akintoye. (2009). Age and skeletal sites affect BMP-2 responsiveness of human bone marrow stromal cells. *Connect Tissue Res* 50:270–277.
44. Yamaguchi A, T Ishizuya, N Kintou, Y Wada, T Katagiri, JM Wozney, V Rosen and S Yoshiki. (1996). Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. *Biochem Biophys Res Commun* 220:366–371.
45. Jäger M, J Fischer, W Dohrn, X Li, DC Ayers, A Czibere, WC Prall, S Lensing-Höhn and R Krauspe. (2008). Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro. *J Orthop Res* 26:1440–1448.
46. Yuasa M, T Yamada, T Taniyama, T Masaoka, W Xuetao, T Yoshii, M Horie, H Yasuda, T Uemura, A Okawa and S Sotome. (2015). Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2. *PLoS One* 10:e0116462.
47. Diefenderfer DL, AM Osyczka, GC Reilly and PS Leboy. (2003). BMP responsiveness in human mesenchymal stem cells. *Connect Tissue Res* 44 Suppl 1:305–311.
48. Osyczka AM, DL Diefenderfer, G Bhargava and PS Leboy. (2004). Different effects of BMP-2 on marrow stromal cells from human and rat bone. *Cells Tissues Organs* 176:109–119.
49. Wang L, NH Dormer, LF Bonewald and MS Detamore. (2010). Osteogenic differentiation of human umbilical cord mesenchymal stromal cells in polyglycolic acid scaffolds. *Tissue Eng Part A* 16:1937–1948.

Address correspondence to:
Prof. Athanasios Mantalaris
Department of Chemical Engineering
and Chemical Technology
South Kensington Campus
Imperial College London
ACEX Building, Room 515
SW7 2AZ London
United Kingdom

E-mail: a.mantalaris@imperial.ac.uk

Received for publication November 4, 2016

Accepted after revision February 17, 2017

Prepublished on Liebert Instant Online February 17, 2017